Trial site
Haematologisch Onkologische Schwerpunktpraxis
Wuerzburg, 97080, GermanyNot linked to an institution yet
- 12running trials
- 2closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 24 trials
- Status
- Active, not recruiting6 trials
- Recruiting6 trials
- Completed2 trials
- Lead sponsor
- Christian Buske3 trials
- Acerta Pharma BV2 trials
- Celgene Corp.2 trials
- BeOne Medicines1 trial
- Dominik Paul Modest1 trial
- and 5 more
Running trials
Not yet recruiting
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Recruiting
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT05099471· Phase 2· Christian Buske· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Active, not recruiting
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS
2022-500430-29-00· Phase 3· Celgene Corp.· Source
Active, not recruiting
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.
2023-509859-13-00· Phase 3· Celgene Corp.· Source
Recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
NCT05008809· Phase 3· Dominik Paul Modest· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
NCT04263480· Phase 2· Christian Buske· Source
Active, not recruiting
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
NCT03620903· Phase 2· Christian Buske· Source
Active, not recruiting
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261· Phase 3· Acerta Pharma BV· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error